Home > Neurology > EAN 2019 > Parkinson's Disease and other Movement Disorders > Opicapone: follow-up on the BIPARK I and II trials

Opicapone: follow-up on the BIPARK I and II trials

Presented By
Prof. Joaquim J. Ferreira, Laboratorio de Farmacologia Clínica e Terapêutica, Faculdade de Medicina de Lisboa, Portugal
Conference
EAN 2019
Trial
Phase 3, BIPARK-I and BIPARK-II
The peripheral catechol-O-methyltransferase (COMT) inhibitor opicapone proved effective in the treatment of motor fluctuations in PD patients in BIPARK-I and II [1,2]. In a post-hoc analysis of these two large, pivotal, multinational trials, opicapone was effective regardless of baseline presence of dyskinesia and of concurrent rasagiline use [3,4]. In another post-hoc analysis, opicapone was effective in reducing motor fluctuations in ‘early fluctuators’, resulting in a significant proportion of responders (achieving at least 1 hour of OFF-time reduction or 1 hour of ON-time increase), similar to the total study population [5]. In the 1-year extension of the BIPARK-I study, the placebo and entacapone groups switched to open-label opicapone. During this period there was no worsening of non-motor symptoms for subjects in these groups [6]. Patients who had switched from placebo presented significantly less disability. At the end of the double-blind pe...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on